Table 2.
Univariate Analysis
| Outcome | E | N | Score | Hazard ratio | Lower CL | Upper CL | P value | Int. dens. | % area |
|---|---|---|---|---|---|---|---|---|---|
| DFS | 58 | 195 | Score 1 | 3.04 | 1.19 | 7.76 | 0.0200 | 0.0217 | 0.0167 |
| DFS | 58 | 195 | Score 2 | 3.18 | 1.11 | 9.17 | 0.0320 | 0.0340 | 0.0256 |
| DFS | 58 | 195 | Score 3 | 1.83 | 1.01 | 3.29 | 0.0447 | 0.0365 | 0.0286 |
| DSS | 52 | 191 | Score 1 | 3.34 | 1.24 | 9.02 | 0.0172 | 0.0176 | 0.0166 |
| DSS | 52 | 191 | Score 2 | 3.46 | 1.12 | 10.72 | 0.0315 | 0.0321 | 0.0301 |
| DSS | 52 | 191 | Score 3 | 1.89 | 1.01 | 3.55 | 0.0479 | 0.0453 | 0.0439 |
A Cox proportional hazard model was fitted to evaluate the association between tumor-associated collagen signature-3 (TACS-3) evaluation scores and disease-specific survival and disease-free survival.
TACS-3 positive patients have a statistically significant poorer survival. The overall hazard ratio, along with upper and lower confidence limits (CL) (95%), and P values were calculated from the univariate analysis. P values for multivariate analysis, which incorporated the measured integrated density (Int. dens.) [representing intensity of the collagen second harmonic generation (SHG) signal] or the percentage area (% area) (number of pixels with SHG signal above threshold/total number of pixels), are shown in the final two columns of the table.
DFS, disease-free survival (ie, patients did not recur); DSS, disease-specific survival (ie, patients did not die from breast cancer); E, number of events; N, total number of cases.